AstraZeneca's Cancer Drug Faces FDA Advisory Panel Rejection
AstraZeneca's oral cancer drug camizestrant was rejected by an FDA advisory panel due to concerns about trial design, leading to a 2% drop in its stock price. The panel voted 6-3 against approval, citing insufficient evidence that the drug improves long-term survival rates. While the company remains optimistic about the drug's future, the rejection may delay its market entry.
Tickers: $AZN
Topics: AstraZeneca breast cancer drug approval pharmaceuticals regulatory decision